⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CNTX News
Context Therapeutics Inc. Common Stock
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
globenewswire.com
CNTX
Form 8-K
sec.gov
CNTX
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
globenewswire.com
CNTX
Form 8-K
sec.gov
CNTX
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CNTX
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
globenewswire.com
CNTX
Form 8-K
sec.gov
CNTX
Form 8-K
sec.gov
CNTX
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
globenewswire.com
CNTX
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CNTX